O	0	1	A
O	2	12	randomized
O	13	18	trial
O	19	21	of
B-intervention	22	32	exemestane
O	33	38	after
O	39	42	two
O	43	45	to
O	46	51	three
O	52	57	years
O	58	60	of
O	61	70	tamoxifen
O	71	78	therapy
O	79	81	in
B-eligibility	82	96	postmenopausal
I-eligibility	97	102	women
I-eligibility	103	107	with
I-eligibility	108	115	primary
I-eligibility	116	122	breast
I-eligibility	123	129	cancer
O	129	130	.

O	131	140	Tamoxifen
O	140	141	,
O	142	147	taken
O	148	151	for
O	152	156	five
O	157	162	years
O	162	163	,
O	164	166	is
O	167	170	the
O	171	179	standard
O	180	188	adjuvant
O	189	198	treatment
O	199	202	for
O	203	217	postmenopausal
O	218	223	women
O	224	228	with
O	229	236	primary
O	236	237	,
O	238	246	estrogen
O	246	247	-
O	247	255	receptor
O	255	256	-
O	256	264	positive
O	265	271	breast
O	272	278	cancer
O	278	279	.

O	280	287	Despite
O	288	292	this
O	293	302	treatment
O	302	303	,
O	304	311	however
O	311	312	,
O	313	317	some
O	318	326	patients
O	327	331	have
O	332	333	a
O	334	341	relapse
O	341	342	.

O	343	345	We
O	346	355	conducted
O	356	357	a
O	358	364	double
O	364	365	-
O	365	370	blind
O	370	371	,
O	372	382	randomized
O	383	388	trial
O	389	391	to
O	392	396	test
O	397	404	whether
O	404	405	,
O	406	411	after
O	412	415	two
O	416	418	to
O	419	424	three
O	425	430	years
O	431	433	of
O	434	443	tamoxifen
O	444	451	therapy
O	451	452	,
O	453	462	switching
O	463	465	to
O	466	476	exemestane
O	477	480	was
O	481	485	more
O	486	495	effective
O	496	500	than
O	501	511	continuing
O	512	521	tamoxifen
O	522	529	therapy
O	530	533	for
O	534	537	the
O	538	547	remainder
O	548	550	of
O	551	554	the
O	555	559	five
O	560	565	years
O	566	568	of
O	569	578	treatment
O	578	579	.

O	580	583	The
O	584	591	primary
O	592	595	end
O	596	601	point
O	602	605	was
B-outcome-Measure	606	613	disease
I-outcome-Measure	613	614	-
I-outcome-Measure	614	618	free
I-outcome-Measure	619	627	survival
O	627	628	.

O	629	631	Of
O	632	635	the
B-total-participants	636	640	4742
O	641	649	patients
O	650	658	enrolled
O	658	659	,
B-intervention-participants	660	664	2362
O	665	669	were
O	670	678	randomly
O	679	687	assigned
O	688	690	to
O	691	697	switch
O	698	700	to
O	701	711	exemestane
O	711	712	,
O	713	716	and
B-control-participants	717	721	2380
O	722	724	to
O	725	733	continue
O	734	736	to
O	737	744	receive
B-control	745	754	tamoxifen
O	754	755	.

O	756	761	After
O	762	763	a
O	764	770	median
O	771	777	follow
O	777	778	-
O	778	780	up
O	781	783	of
O	784	786	30
O	786	787	.
O	787	788	6
O	789	795	months
O	795	796	,
O	797	800	449
O	801	806	first
O	807	813	events
O	814	815	(
B-outcome	815	820	local
I-outcome	821	823	or
I-outcome	824	834	metastatic
I-outcome	835	845	recurrence
O	845	846	,
B-outcome	847	860	contralateral
I-outcome	861	867	breast
I-outcome	868	874	cancer
O	874	875	,
O	876	878	or
B-outcome	879	884	death
O	884	885	)
O	886	890	were
O	891	899	reported
O	899	900	-
O	900	901	-
B-iv-bin-abs	901	904	183
O	905	907	in
O	908	911	the
O	912	922	exemestane
O	923	928	group
O	929	932	and
B-cv-bin-abs	933	936	266
O	937	939	in
O	940	943	the
O	944	953	tamoxifen
O	954	959	group
O	959	960	.

O	961	964	The
O	965	975	unadjusted
O	976	982	hazard
O	983	988	ratio
O	989	991	in
O	992	995	the
O	996	1006	exemestane
O	1007	1012	group
O	1013	1015	as
O	1016	1024	compared
O	1025	1029	with
O	1030	1033	the
O	1034	1043	tamoxifen
O	1044	1049	group
O	1050	1053	was
O	1054	1055	0
O	1055	1056	.
O	1056	1058	68
O	1059	1060	(
O	1060	1062	95
O	1063	1070	percent
O	1071	1081	confidence
O	1082	1090	interval
O	1090	1091	,
O	1092	1093	0
O	1093	1094	.
O	1094	1096	56
O	1097	1099	to
O	1100	1101	0
O	1101	1102	.
O	1102	1104	82
O	1104	1105	;
O	1106	1107	P
O	1107	1108	<
O	1108	1109	0
O	1109	1110	.
O	1110	1113	001
O	1114	1116	by
O	1117	1120	the
O	1121	1124	log
O	1124	1125	-
O	1125	1129	rank
O	1130	1134	test
O	1134	1135	)
O	1135	1136	,
O	1137	1149	representing
O	1150	1151	a
B-iv-bin-percent	1152	1154	32
I-iv-bin-percent	1155	1162	percent
B-outcome	1163	1172	reduction
I-outcome	1173	1175	in
I-outcome	1176	1180	risk
O	1181	1184	and
O	1185	1198	corresponding
O	1199	1201	to
O	1202	1204	an
O	1205	1213	absolute
O	1214	1221	benefit
O	1222	1224	in
O	1225	1230	terms
O	1231	1233	of
B-outcome	1234	1241	disease
I-outcome	1241	1242	-
I-outcome	1242	1246	free
I-outcome	1247	1255	survival
O	1256	1258	of
B-iv-bin-percent	1259	1260	4
I-iv-bin-percent	1260	1261	.
I-iv-bin-percent	1261	1262	7
I-iv-bin-percent	1263	1270	percent
O	1271	1272	(
O	1272	1274	95
O	1275	1282	percent
O	1283	1293	confidence
O	1294	1302	interval
O	1302	1303	,
O	1304	1305	2
O	1305	1306	.
O	1306	1307	6
O	1308	1310	to
O	1311	1312	6
O	1312	1313	.
O	1313	1314	8
O	1314	1315	)
O	1316	1318	at
O	1319	1324	three
O	1325	1330	years
O	1331	1336	after
O	1337	1350	randomization
O	1350	1351	.

B-outcome	1352	1359	Overall
I-outcome	1360	1368	survival
O	1369	1372	was
O	1373	1376	not
O	1377	1390	significantly
O	1391	1400	different
O	1401	1403	in
O	1404	1407	the
O	1408	1411	two
O	1412	1418	groups
O	1418	1419	,
O	1420	1424	with
B-iv-bin-abs	1425	1427	93
B-outcome	1428	1434	deaths
O	1435	1444	occurring
O	1445	1447	in
O	1448	1451	the
O	1452	1462	exemestane
O	1463	1468	group
O	1469	1472	and
B-cv-bin-abs	1473	1476	106
O	1477	1479	in
O	1480	1483	the
O	1484	1493	tamoxifen
O	1494	1499	group
O	1499	1500	.

B-outcome	1501	1507	Severe
I-outcome	1508	1513	toxic
I-outcome	1514	1521	effects
O	1522	1524	of
O	1525	1535	exemestane
O	1536	1540	were
O	1541	1545	rare
O	1545	1546	.

B-outcome	1547	1560	Contralateral
I-outcome	1561	1567	breast
I-outcome	1568	1574	cancer
O	1575	1583	occurred
O	1584	1586	in
B-cv-bin-abs	1587	1589	20
O	1590	1598	patients
O	1599	1601	in
O	1602	1605	the
O	1606	1615	tamoxifen
O	1616	1621	group
O	1622	1625	and
B-iv-bin-abs	1626	1627	9
O	1628	1630	in
O	1631	1634	the
O	1635	1645	exemestane
O	1646	1651	group
O	1652	1653	(
O	1653	1654	P
O	1654	1655	=
O	1655	1656	0
O	1656	1657	.
O	1657	1659	04
O	1659	1660	)
O	1660	1661	.

O	1662	1672	Exemestane
O	1673	1680	therapy
O	1681	1686	after
O	1687	1690	two
O	1691	1693	to
O	1694	1699	three
O	1700	1705	years
O	1706	1708	of
O	1709	1718	tamoxifen
O	1719	1726	therapy
O	1727	1740	significantly
O	1741	1749	improved
O	1750	1757	disease
O	1757	1758	-
O	1758	1762	free
O	1763	1771	survival
O	1772	1774	as
O	1775	1783	compared
O	1784	1788	with
O	1789	1792	the
O	1793	1801	standard
O	1802	1806	five
O	1807	1812	years
O	1813	1815	of
O	1816	1825	tamoxifen
O	1826	1835	treatment
O	1835	1836	.
